GNLX

#3367
Genelux Corporation - Common Stock
3.0 5 USD
-2.24%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
3.05
3.05
년간 변동
2.29
8.54
일일 변동
-2.24%
월간 변동
+21.51%
6달 변화
-44.55%
년간 변동율
+25.51%
이전 종가
3.1 2
Open
3.0 5
저가
3.0 5
High
3.0 5
양
8
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 136.76 M
  • Employee 26
  • Founded 2001
  • CEO N/A
  • Website www.genelux.com
  • Headquarter Delaware, United States
  • FIGI BBG0044BNBX6
  • Industry 생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-5.07
주가매출액비율
20.26 K

Genelux Corporation - Common Stock

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

뉴스